Bristol-Myers Squibb: In the Pipeline
 
 
 

In the Pipeline | July 10, 2014

Compound /
Generic Name

Brand Name

Phase

Modality /
Compound Type

Disease
Areas

IKur Inhibitor
1
Small Molecule
Cardiovascular
PAR4 Antagonist
1
Small Molecule
Cardiovascular
Factor XIa Inhibitor
1
Small Molecule
Cardiovascular
Apixaban
M
Small Molecule
Cardiovascular
CCR2 / 5 Antagonist (2)
1
Small Molecule
Fibrotic Diseases
LPA1 Antagonist
2
Small Molecule
Fibrotic Diseases
CCR2 / 5 Antagonist (1)
2
Small Molecule
Fibrotic Diseases
Anti-Myostatin
1
Biologic
Genetically Defined         Diseases
Elotuzumab
3
Biologic
Immuno-Oncology
Ipilimumab
M
Biologic
Immuno-Oncology
Nivolumab
3
Biologic
Immuno-Oncology
Anti-KIR Lirilumab
1
Biologic
Immuno-Oncology
Anti-LAG3
1
Biologic
Immuno-Oncology
Anti-CD137 Urelumab
1
Biologic
Immuno-Oncology
Anti-CD28
1
Biologic
Immunoscience
Anti-CD40L
1
Biologic
Immunoscience
Abatacept
M
Biologic
Immunoscience
Anti-IL31
1
Biologic
Immunoscience
Anti-CD40
1
Biologic
Immunoscience
Belatacept
M
Biologic
Immunoscience
PEG-FGF21
1
Biologic
Metabolics
Notch Inhibitors
1
Small Molecule
Oncology
Dasatinib
M
Small Molecule
Oncology
Anti-CXCR4 Ulocuplumab
1
Biologic
Oncology
HIV Attachment Inhibitor
2
Small Molecule
Virology
Anti-PD-L1
1
Biologic
Virology
Asunaprevir
SUNVEPRA*
M
Small Molecule
Virology
NS5B non- nucleoside inhibitor
3
Small Molecule
Virology
Atazanavir sulfate
M
Small Molecule
Virology
Entecavir
M
Small Molecule
Virology
HIV Program +
2
Small Molecule
Virology
Daclatasvir
DAKLINZA^
M
Small Molecule
Virology
reset >

Explore Our Pipeline


Customize View

Development Phase
1 - Phase I
2 - Phase II
3 - Phase III
M - Marketed Product       Development
Modality/Compound Type
Biologic
Small Molecule
Disease Areas

+Mechanism of Action is not disclosed

^DAKLINZA is not approved in the U.S.
*SUNVEPRA is not approved in the U.S.

Please click on product name to see the Full U.S. Prescribing Information for ELIQUIS®, ERBITUX®, NULOJIX®, ORENCIA®, REYATAZ®, SPRYCEL®, YERVOY®, including boxed WARNINGS for BARACLUDE®, ELIQUIS®, NULOJIX®, and Boxed WARNING for YERVOY® regarding immune-mediated adverse reactions and Boxed WARNINGS for ERBITUX® regarding infusion reactions and cardiopulmonary arrest.

Phase I – clinical trials investigating safety of an investigational medicine in a small number of human subjects.

Phase II – clinical trials investigating dosing, safety and efficacy of an investigational medicine in a small number of patients who have the disease or condition under study.

Phase III – clinical trials investigating the safety and efficacy of an investigational medicine in a larger number of patients who have the disease or condition under study. For purposes of this chart, this includes the regulatory approval process prior to receiving marketing approval in the first major market.

Marketed Product Development – clinical trials investigating new uses or formulations regarding medicines that have already received regulatory approval for at least one indication in a major market.

Like any other scientific endeavor, clinical testing of novel drug compounds is a complex, time-consuming, resource-intensive process with no guaranteed results. But, as described here, Bristol-Myers Squibb is committed to pursuing such clinical development and, in doing so, to bringing new hope to patients.

 
 
 
 
 


You are leaving BMS.com to go to the Amylin Job Search and application tool. IMPORTANT TO NOTE: This may require a separate login and password than what is used for the Bristol-Myers Squibb search and application process.
You are leaving BMS.com to go to the Amylin Job Search and application tool. IMPORTANT TO NOTE: This may require a separate login and password than what is used for the Bristol-Myers Squibb search and application process.